Welcome to our dedicated page for Vascular Biogenics Ltd. news (Ticker: vblt), a resource for investors and traders seeking the latest updates and insights on Vascular Biogenics Ltd. stock.
Vascular Biogenics Ltd. (Nasdaq: VBLT), commonly known as VBL Therapeutics, is a leading biotechnology company headquartered at 6 Yonatan Netanyahu Street, Yehud, Center District, Israel. The company is dedicated to the discovery, development, and commercialization of innovative therapies for treating cancer and immune-inflammatory diseases. Its mission is to transform the standard of care in oncology through precision medicines.
Recently, VBL Therapeutics has made significant strides in its corporate journey. On August 14, 2023, the company announced its financial results for the second quarter ending June 30, 2023, and provided updates on its ongoing merger with Notable Labs, Inc. This merger is seen as a pivotal move, aiming to combine VBL's cutting-edge technologies with Notable's Predictive Precision Medicines Platform. The merger is anticipated to create a robust entity focused on developing a pipeline of clinical-stage precision medicines.
On September 6, 2023, the company's registration statement on Form S-4 was declared effective by the U.S. Securities and Exchange Commission (SEC), marking a critical milestone towards completing the merger. Following the approval from VBL’s shareholders at the annual and special meeting held on October 12, 2023, the merger is expected to close around October 16, 2023. Post-merger, VBL will be renamed 'Notable Labs, Ltd.' and will trade under the new symbol 'NTBL' on the Nasdaq Capital Market.
The merger with Notable Labs is expected to leverage Notable's technology to enhance VBL’s existing pipeline, offering a promising future for patients and shareholders alike. The combined organization aims to advance precision medicines that could significantly improve patient outcomes in oncology.
VBL Therapeutics (Nasdaq: VBLT) announced that the FDA granted Fast Track designation for their investigational drug, ofra-vec, in combination with paclitaxel, targeting platinum-resistant ovarian cancer. This designation aims to expedite the development and review of therapies to meet serious medical needs. The OVAL Phase 3 trial has completed enrollment with 409 patients, and top-line data on progression-free survival is expected in 2H 2022. A positive outcome may lead to a Biologics License Application submission in 1H 2023, potentially accelerating market availability.
VBL Therapeutics (Nasdaq: VBLT) announced a key opinion leader seminar focused on ovarian cancer treatment on April 11, 2022, at 12 PM EDT in New York City. The event features experts Bradley J. Monk, Richard Penson, and Kathleen Moore, discussing the current treatment landscape and unmet medical needs. VBL’s lead candidate, ofra-vec, will be highlighted for its potential to treat platinum-resistant ovarian cancer as part of the ongoing OVAL Phase 3 clinical trial, which is fully enrolled with 409 patients. Topline data is expected in the second half of 2022.
VBL Therapeutics (Nasdaq: VBLT) announced its financial results for 2021 and shared updates on its clinical programs, highlighting the completion of patient enrollment in the Phase 3 OVAL trial for platinum-resistant ovarian cancer. The company expects top-line data on progression-free survival in 2H 2022, with plans to submit a Biologics License Application in 1H 2023 if results are positive. VBL also reported a net loss of $29.9 million, a slight increase from the previous year, with revenues at $0.8 million. The cash reserves are projected to cover expenses for the next 12 months.
VBL Therapeutics (Nasdaq: VBLT) announced it will release its financial results for the year ended December 31, 2021, on March 23, 2022. The release will be followed by a conference call at 8:30 AM ET, hosted by CEO Dror Harats and CFO Sam Backenroth, to discuss the results and provide a corporate update. VBL is focused on developing first-in-class therapeutics for difficult-to-treat cancers, leveraging its VTS™ gene-based platform and antibody-monocyte targeting technology. The lead candidate, ofranergene obadenovec, is in a Phase 3 trial for platinum-resistant ovarian cancer.
VBL Therapeutics (Nasdaq: VBLT) will announce its financial results for the year ended December 31, 2021, on March 23, 2022. The release will precede a conference call at 8:30 AM ET, featuring CEO Dror Harats and CFO Sam Backenroth, who will discuss the results and provide a corporate update. VBL Therapeutics is a late-stage biotechnology company focused on developing innovative treatments for challenging malignant solid tumors and inflammatory indications, with their lead candidate, ofranergene obadenovec, undergoing a Phase 3 trial for platinum-resistant ovarian cancer.
VBL Therapeutics has completed enrollment in its Phase 3 OVAL trial, focusing on recurrent platinum-resistant ovarian cancer, with 409 patients enrolled globally across various regions.
The trial's top-line data for progression-free survival (PFS) is expected in the second half of 2022, potentially enabling a Biologics License Application (BLA) submission. An independent Data Safety Monitoring Committee (DSMC) unanimously recommended continuing the trial after reviewing data from over 90% of the enrolled patients.
VBL Therapeutics (Nasdaq: VBLT) announced participation in two significant investor conferences: the 34th Annual Roth Conference and the 32nd Annual Oppenheimer Healthcare Conference. Management will take part in a fireside chat on March 14, 2022, at 9:30 AM PT and on March 16, 2022, at 8:40 AM ET. Investors can access the webcasts via links provided in the announcement. VBL Therapeutics focuses on developing innovative treatments for challenging malignant solid tumors and inflammatory conditions, with their lead candidate ofranergene obadenovec (ofra-vec) in a Phase 3 trial for ovarian cancer.
VBL Therapeutics (Nasdaq: VBLT) announced the grant of a non-qualified stock option to Matthew Trudeau, effective February 13, 2022. This grant includes the option to purchase 300,000 ordinary shares at an exercise price of $1.51 each, aligning with the market value on the grant date. The option will vest beginning one year after the grant, with 33% vesting immediately, and the remainder vesting quarterly over the next two years, contingent on continued employment. This move adheres to Nasdaq Listing Rule 5635(c)(4) and supports VBL's growth in developing therapies for malignant solid tumors and inflammatory conditions.
VBL Therapeutics (Nasdaq: VBLT), a biotechnology firm focused on innovative cancer treatments, announced participation in two upcoming conferences. CEO Dror Harats will engage in a fireside chat at the Guggenheim Oncology Conference on February 10, 2022, at 10:00 a.m. ET. Additionally, the company will attend the BIO CEO & Investor Conference from February 14-17, 2022. VBL Therapeutics is advancing its lead candidate, ofranergene obadenovec (VB-111), currently in a Phase 3 trial for platinum-resistant ovarian cancer. For webcast details, visit their website.
On January 18, 2022, VBL Therapeutics (Nasdaq: VBLT) announced the appointment of Matthew Trudeau as Chief Commercial Officer (CCO), a move aimed at advancing the commercialization of their lead product, ofra-vec (VB-111). Trudeau's extensive experience in launching complex biologics, particularly in oncology, positions VBL to enhance its market presence as the OVAL Phase 3 trial for ovarian cancer progresses. Enrollment in the study is expected to complete soon, with co-primary endpoint readouts anticipated in the second half of 2022, which could facilitate a BLA filing.
FAQ
What is the market cap of Vascular Biogenics Ltd. (vblt)?
What does Vascular Biogenics Ltd. specialize in?
Where is Vascular Biogenics Ltd. located?
What recent corporate event did VBL announce?
What is the significance of the merger with Notable Labs?
When is the merger expected to be completed?
What will VBL be renamed after the merger?
What will be the new trading symbol for VBL after the merger?
What recent approvals did VBL receive for the merger?
Who is the CEO of VBL Therapeutics?
How will the merger benefit patients?
